Overview

HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the potential PK interaction of multiple oral doses of HCV-796 and a single oral dose of midazolam when coadministered to healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Midazolam